Subscribe

Eckert & Ziegler SE (EUZ.DE)

EUR14.31 -0.12 (-0.83%)
DE XETRA Healthcare Medical - Specialties
Address Robert-Rössle-Straße 10 13125
Berlin, DE
CEO Harald Hasselmann
Website ezag.com
IPO 1999-05-26
ISIN DE0005659700

Explore sections of this company profile

Also trades on Deutsche Börse · EUZ.DE (EUR) London Stock Exchange · 0NZY.L (EUR)
Description

Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration-related sources for radioisotopes. In addition, the company offers Tc-99m generators and supplies, trade in raw isotopes and other products, and services. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR14.31 -0.12 (-0.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
114.8K
Beta
1.48
Float Shares
40.96M
Free Float %
65.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.94% -5.19% -0.80% -1.07% -12.17% -2.37% -23.99% -9.70% -40.92% +770.59% +687.23%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
14.31
DCF (Unlevered) 6.30 -55.9%
DCF (Levered) 8.95 -37.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 3 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
4.86
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Specialties: +8.3%
    +5.5% Q1'26: +7.0% (vs Q1'25)
  • ✓
    EPS growth Medical - Specialties: +10.1%
    +47.2% ★ Q1'26: +13.3% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Specialties: +51.3%
    +11.5% Q1'26: +0.0% (vs Q1'25)
  • ✓
    EBIT margin Medical - Specialties: +12.6%
    +24.1% ★ Q1'26: +23.5% (vs Q1'25)
  • ✓
    ROIC Medical - Specialties: +6.6%
    +30.0% ★ Q1'26: +24.2% (vs Q1'25)
  • ✗
    Share dilution Medical - Specialties: 0.0%
    +0.4% Q1'26: +0.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×
    0.49× ★ Q1'26: 0.51× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.48) × ERP
WACC = 95% × Ke + 5% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 6.31 Current price: 14.31
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2009
actual 		Dec 2010
actual 		Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
3 EPS Ana. 		Dec 2027
3 Rev. Ana.
3 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
101.40M
est: 106.98M (-5.2%)
111.09M
est: 109.06M (+1.9%)
116.20M
est: 113.27M (+2.6%)
120.00M
est: 119.36M (+0.5%)
117.14M
est: 122.17M (-4.1%)
127.26M
est: 128.90M (-1.3%)
140.05M
est: 136.90M (+2.3%)
137.94M
est: 139.95M (-1.4%)
138.63M
est: 140.50M (-1.3%)
168.71M
est: 165.10M (+2.2%)
178.49M
est: 180.40M (-1.1%)
176.14M
est: 171.50M (+2.7%)
180.44M
est: 179.60M (+0.5%)
222.26M
est: 229.00M (-2.9%)
246.09M
est: 273.51M (-10.0%)
295.85M
est: 295.00M (+0.3%)
311.96M
est: 314.30M (-0.7%)
322.88M
317.24M – 331.13M
+2.7% YoY
351.06M
341.75M – 360.28M
+8.7% YoY
388.53M
384.12M – 392.95M
+10.7% YoY
EBITDA
28.01M
est: 28.09M (-0.3%)
26.71M
est: 18.07M (+47.8%)
30.63M
est: 21.33M (+43.6%)
28.00M
est: 25.41M (+10.2%)
22.65M
est: 21.75M (+4.1%)
20.57M
est: 24.22M (-15.1%)
27.15M
est: 19.93M (+36.2%)
25.32M
est: 25.16M (+0.6%)
26.87M
est: 22.90M (+17.3%)
31.95M
est: 32.94M (-3.0%)
39.45M
est: 31.71M (+24.4%)
43.05M
est: 40.41M (+6.5%)
56.68M
est: 44.76M (+26.6%)
57.90M
est: 49.04M (+18.1%)
59.67M
est: 75.16M (-20.6%)
77.38M
est: 81.22M (-4.7%)
92.13M
est: 86.37M (+6.7%)
88.73M
87.18M – 90.99M
+2.7% YoY
96.47M
93.91M – 99.00M
+8.7% YoY
106.77M
105.55M – 107.98M
+10.7% YoY
EBIT
16.49M
est: 15.19M (+8.5%)
16.87M
est: 15.80M (+6.8%)
23.12M
est: 19.01M (+21.6%)
20.25M
est: 24.03M (-15.7%)
13.46M
est: 20.37M (-33.9%)
13.68M
est: 11.29M (+21.2%)
18.79M
est: 13.13M (+43.1%)
16.58M
est: 18.30M (-9.4%)
18.22M
est: 15.45M (+17.9%)
23.56M
est: 23.56M (0.0%)
32.34M
est: 24.18M (+33.7%)
32.34M
est: 30.81M (+5.0%)
47.13M
est: 34.12M (+38.1%)
47.04M
est: 37.39M (+25.8%)
46.30M
est: 61.63M (-24.9%)
66.57M
est: 55.22M (+20.6%)
75.06M
est: 70.82M (+6.0%)
72.75M
71.48M – 74.61M
+2.7% YoY
79.10M
77.00M – 81.18M
+8.7% YoY
87.54M
86.55M – 88.54M
+10.7% YoY
Net Income
21.89M
est: 7.12M (+207.4%)
10.42M
est: 13.56M (-23.2%)
10.42M
est: 9.76M (+6.7%)
10.29M
est: 10.96M (-6.1%)
9.09M
est: 10.54M (-13.8%)
6.78M
est: 9.60M (-29.4%)
10.72M
est: 7.22M (+48.4%)
9.55M
est: 11.08M (-13.8%)
14.70M
est: 9.59M (+53.3%)
16.13M
est: 18.05M (-10.6%)
22.02M
est: 16.82M (+30.9%)
21.29M
est: 21.45M (-0.8%)
34.53M
est: 23.76M (+45.3%)
29.28M
est: 26.03M (+12.5%)
26.30M
est: 114.01M (-76.9%)
33.28M
est: 41.50M (-19.8%)
48.76M
est: 48.76M (+0.0%)
52.28M
52.01M – 52.81M
+7.2% YoY
54.93M
54.21M – 58.89M
+5.1% YoY
62.20M
61.40M – 65.35M
+13.2% YoY
SGA
37.51M
est: 41.93M (-10.6%)
37.76M
est: 34.25M (+10.2%)
38.75M
est: 34.59M (+12.0%)
18.27M
est: 37.09M (-50.8%)
18.53M
est: 39.92M (-53.6%)
19.63M
est: 42.52M (-53.8%)
21.56M
est: 47.79M (-54.9%)
15.57M
est: 47.87M (-67.5%)
17.50M
est: 45.11M (-61.2%)
19.37M
est: 48.20M (-59.8%)
20.60M
est: 47.56M (-56.7%)
19.65M
est: 44.47M (-55.8%)
20.60M
est: 49.24M (-58.2%)
22.56M
est: 53.95M (-58.2%)
25.30M
est: 27.58M (-8.3%)
27.88M
est: 65.59M (-57.5%)
28.53M
est: 31.69M (-10.0%)
32.56M
31.99M – 33.39M
+2.7% YoY
35.40M
34.46M – 36.33M
+8.7% YoY
39.18M
38.73M – 39.62M
+10.7% YoY
EPS
0.29
est: 0.45 (-34.2%)
0.15
est: 0.47 (-67.9%)
0.17
est: 0.52 (-68.0%)
0.16
est: 0.50 (-67.6%)
0.14
est: 0.43 (-66.6%)
0.11
est: 0.42 (-74.7%)
0.17
est: 0.45 (-62.2%)
0.15
est: 0.13 (+11.6%)
0.23
est: 0.17 (+40.0%)
0.26
est: 0.23 (+15.1%)
0.36
est: 0.32 (+9.9%)
0.37
est: 0.31 (+20.1%)
0.56
est: 0.39 (+43.4%)
0.47
est: 0.47 (+0.4%)
0.42
est: 1.81 (-76.8%)
0.53
est: 0.67 (-21.3%)
0.78
est: 0.94 (-16.6%)
0.83
0.83 – 0.84
-11.0% YoY
0.90
0.86 – 0.94
+7.7% YoY
1.01
0.98 – 1.04
+12.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 B+ 3/5 3/5 5/5 5/5 2/5 2/5 2/5
2026-05-08 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-05-07 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-05-06 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-05-05 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-05-04 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-30 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-29 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-28 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-27 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-24 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-23 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-22 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-21 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-20 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-17 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5
2026-04-16 A- 4/5 3/5 5/5 5/5 2/5 3/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
41.28M
OE per share TTM
0.57
Owner's Yield
4.28%
Maintenance CapEx ratio
28.97%
Maint CapEx / Avg PPE
42.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 92 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Amundi SDAX UCITS ETF Dist C005.DE 1.69% 3.01M 0.70%
2 Amundi TecDAX UCITS ETF Dist E908.DE 0.55% 513.5K 0.40%
3 iShares TecDAX UCITS ETF (DE) EXIB.DE 0.52% 67.4K 0.51%
4 iShares TecDAX UCITS ETF (DE) EXS2.DE 0.52% 3.67M 0.51%
5 UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE 0.12% 919.7K 0.33%
6 iShares MSCI EMU Small Cap UCITS ETF CES1.L 0.12% 1.25M 0.58%
7 WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L 0.09% 81.5K 0.38%
8 WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE 0.09% 81.5K 0.38%
9 iShares Healthcare Innovation UCITS ETF HEAL.L 0.08% 895.3K 0.40%
10 Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA 0.08% 546.4K 0.40%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
67.3K
Shares Outstanding
62.57M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Harald Hasselmann Chief Executive Officer & Chairman of the Executive Board of Medical Segment 636.8K —
Ivan Simmer Managing Director of Eckert & Ziegler Cesio s.r.o. — —
Gunnar Mann COO & Member of the Executive Board — —
Julian Schröder Head of Group Controlling — —
Karolin Riehle Head of Investor Relations & PR — female
Richard Hunter Vice President Sales & Marketing — —
Joseph Hathcock Chief Operating Officer of Segment Isotope Products — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Specialties